DOCSLIB.ORG

SUPPLEMENT to SYNOPSIS of DEBATE ______(Proceedings Other Than Questions and Answers) ______Tuesday, July 20, 2021 / Ashadha 29, 1943 (Saka) ______

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SUPPLEMENT to SYNOPSIS of DEBATE ______(Proceedings Other Than Questions and Answers) ______Tuesday, July 20, 2021 / Ashadha 29, 1943 (Saka) ______ RAJYA SABHA _______ SUPPLEMENT TO SYNOPSIS OF DEBATE _______ (Proceedings other than Questions and Answers) _______ Tuesday, July 20, 2021 / Ashadha 29, 1943 (Saka) _______ SHORT DURATION DISCUSSION The management of COVID-19 pandemic, implementation of vaccination policy and challenges of the likely third wave - Contd. SHRI VAIKO: My heart of sorrow goes towards the people, frontline warriors, doctors, nurses and the medical staff who have lost their lives in their endeavour to save the people affected by corona. Since ancient times endemics and pandemics are happening across the world till now. Lakhs and crores of peoples died due to these phenomena. The human civilization has been getting badly affected at intervals. Now, it is Covid-19 or Coronavirus which has come and is killing countless people. There is news that the third wave may come. Even there is a possibility of coming of fourth wave also. The haves and have-nots, the poor people could not afford to get this oxygen and they had to face the end of life. In Chengalpattu and Ooty in Tamil Nadu, vaccine manufacturing companies should be supported by the Central Government. ___________________________________________________ This Synopsis is not an authoritative record of the proceedings of the Rajya Sabha. 33 DR. VINAY P. SAHASRABUDDHE: After almost a century, this country has been engulfed by the Corona tragedy. All the Hon'ble Members expressed their respect and gratitude towards our health workers, doctors, nurses, police and sanitation workers. Hon'ble Prime Minister appealed to the people to express their gratitude towards these very health workers. Every effort of the Prime Minister is opposed. It is ideological and personal jaundice from which they should come out. We have faced this tragedy while maintaining democracy. The democracy of this country is like our respiratory system and the commitment of Hon'ble Prime Minister towards good governance and development is like the immune system. This should be kept in mind. SHRI BINOY VISWAM: I request the Minister that what has happened to the PM Cares Fund. In this country, five lakhs people died. Crores and crores of people lost their jobs. The system failed, the Government failed, let us unite and fight to overcome the failures. I request the Minister to explain us whether he has a plan to devote more funds for healthcare; whether he has a plan for complete and free vaccination which we call universal vaccination at the earliest. The only solution is vaccination. The government has said that Rs.35,000 crores are earmarked for this purpose. And the country needs Rs.34,400 crores for absolute and complete vaccination. So, the money is there. I come from the State of Kerala where even though the number of patients is not very small but the rate of deaths is the lowest in the country. We have an excellent health system there and PHC is the soul of it. It is spread over the State and we could activate that. In the beginning, in the Obituary, it would have been better and sensitive to say one sentence at least about the Corona victims. We fail to do it. Please, increase the health allocation, please activate the under-utilized public sector companies of pharmaceuticals in this country and then we can have the maximum production of vaccines. please, take care of those children whose parents have died due to Corona. please, provide smart phones to all the needy children of the poor sections of the country. Then, give money to the poor people. The government is giving packages and packages. This is very good, but people have no money. please give money to them to survive. 34 DR. ANIL JAIN: I think vaccination is the most effective and last way to fight corona in the world. As far as the management of Corona is concerned, no one had any idea of the so rapid spread of this pandemic. We were in the very bad condition in the world in terms of health infrastructure. Despite this, the government fought against Corona on the front foot with limited resources. The era of Corona was made a blessing in disguise, we had limited resources, but we tried to convert this disaster into an opportunity. Not only the government, the people of the country also did this work, the people of the country were encouraged. The Minister of Finance of the country announced a package of 1 lakh, 17 thousand crores on 26 March so that the citizens of the country are not inconvenienced. Food packets were given to more than 25 crore people. The Prime Minister had publicly said in February that Corona was not over yet. The Prime Minister had warned in the meeting of Chief Ministers on 15 or 16 March that Corona is not over yet. Earlier, there was a requirement of 900 tonnes of oxygen in the country, this requirement has increased to 11,000 tonnes. We have to stop the third wave. Today everyone wants to get the vaccine. You should publicize your photo while getting the vaccine so that the public can also be inspired to get the vaccine. THE MINISTER OF STATE IN THE MINISTRY OF SOCIAL JUSTICE AND EMPOWERMENT (SHRI RAMDAS ATHAWALE): All the people related to health, sanitation and law and order have contributed in the fight against Corona. I gave the slogan 'Go Corona'. I also congratulate those who did not get corona. We should not do politics on this. THE MINSITER OF PETROLEUM AND NATURAL GAS; AND THE MINISTER OF HOUSING AND URBAN AFFAIRS (SHRI HARDEEP SINGH PURI): Every single death of any Indian citizen on account of any cause, is a serious matter and is a matter of regret. The virus is our enemy. Fatality rate of SARS is higher that the fatality rate of Covid-19. Millions of people had died of Spanish flu. We were first who stopped the flights coming from China. We went into a total lockdown. But we are told that the lockdown was too severe. When we went into a complete lockdown, the country had not enough medical infrastructure. Initially we imported medical 35 equipment but later we started manufacturing each of these things and started exporting them. This is the achievement. Bharat Biotech and Serum Institute were initially producing the vaccine for India. But we were questioned on this too. You should know that we are also a part of international agreements. Supply chain inputs come from outside the country and you are making politics out of this. We will meet our domestic demand soon. You can see, what is being done with the vaccines in Rajasthan and Punjab. We produced vaccines domestically and shared our expertise, our abilities, and our supplies with our immediate neighbour, as a part of one large family. We are importing also. But, some people wanted to fuel vaccine hesitancy. It was told that domestic vaccine was not effective. May be, they want to have expensive imported vaccines. Two Chief Ministers said that the Centre should not do the vaccine procurement and let the States do it. The hon. Prime Minister agreed to that. But, when the States were not able to do, it is then the Centre that procured them in order to provide them free to the States. The hon. Prime Minister, on 17th March, after speaking to the Chief Ministers of States, had warned them to be careful because the numbers were rising. And, then, there were only 30,000 cases in the country. But, some of them did not listen to that warning. SHRI ANAND SHARMA: We are very proud, as a nation, of our scientists, of our doctors, of our paramedics, of our epidemiologists and of our vaccine manufacturers. However, India has not been recognized today for its vaccine manufacturing ability. In 1990s, India became the largest vaccine manufacturer of the world. No Government, in Independent India, had faced a pandemic. That is the truth because the last pandemic was in 1918. In fact, the second wave was very tough. This affected the metropolis, towns and villages. We have seen very heartbreaking scenes in this pandemic. This tragedy also occurred in other parts of the world. There is uncertainty about the third wave. The government should inform the country when the third wave will come. No one can say for sure how severe the third wave will be, how many people will be affected by it. No doctor and scientist can tell about the Covid variants. It is also not known whether the vaccine will prove to be effective for the delta variant or delta plus. We should have prepared by drawing lesson from the first wave. This preparedness should be maintained in partnership between the Central Government 36 and the State Governments. After the first wave, there was some complacency and the administration was not prepared. Many facilities that were created during the first wave all over the country were deactivated. We did not realise pandemics have a pattern; the second wave will be more severe; the third wave will come; then, the fourth will come. That is why the Government must ensure today that the facilities that were created must remain in a state of readiness for the third wave. And this is a fact that we grappled with the oxygen shortage and the oxygen requirement suddenly skyrocketed. Industrial oxygen got diverted. We ramped up the facilities. This being a global challenge, other countries came to our help. We were not in a position, in the month of second-half of April and in the month of May, to save our people.
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • In 2020, India Dealt with the First Wave of COVID-19 Pandemic With
    PREFACE n 2020, India dealt with the first wave of COVID-19 pandemic with collective measures, Iscientific approach, and awareness. Undoubtedly the second wave of the pandemic is testing our patience and the extent to which we can all tolerate its fangs. The impact of the second wave has seen shortage of medical oxygen across the nation. But, the intelligent use of technology and well-planned resource allocation to tackle the new wave of the pandemic has been dealt with at a war-footing. The current edition, COVID 2021: Nation’s S&T Efforts Against COVID-19, has been compiled to inform our readers and strengthen the usefulness of any published information. This edition contains compilation and coverage of information related to the capacity enhancement of medical oxygen, start-up spotlights, research contributions, and so on. To bridge the gap among scientific contributions, leadership and administrative efforts, and the perspective of the general public, Vigyan Prasar is continuously reaching out to its audiences in the shape of a regular e-newsletter, taking its mandate of science communication, popularisation and extension to the next level. Our effort is firmly based on the fact that “Science gathers knowledge faster than society gathers wisdom”. The steady increase in the number of recoveries and the significant and continuous decrease in positivity rate provide us the much-needed assurance that this may be the outcome of improving the health infrastructure and making health the cornerstone at the policy level. We wish an engaging reading to our audiences across all strata of the society and look forward to suggestions and feedback at [email protected].
    [Show full text]
  • Lok Sabha Secretariat (LARRDIS) New Delhi
    Lok Sabha Secretariat (LARRDIS) New Delhi BACKGROUND NOTE on “Status of COVID - 19 Vaccine production in India” (For the use of the Standing Committee on Chemicals and Fertilisers) October 2020 ____________________________________________________________________________ The brief note is intended to serve only as a background aid to the Standing Committee on Chemical and Fertilisers. It is for restricted circulation and not for publication in any form. [Prepared by the Educational & Scientific Affairs Wing of the R&I Division. Officers associated with the preparation - Babulal Naik, Additional Director;Ms. Namita Kumari, RO; supervised by Shri Pradosh Panda, Director. Feedback is welcome and may be sent to [email protected]] Status of COVID - 19 vaccine production in India LARRDIS October 2020 Introduction India has the world's second largest coronavirus cases after the United States. However, after 8 months since the pandemic hit the country, the rising per day COVID cases curve has started to decline, especially at a time when a possible launch of coronavirus vaccine is being hoped by many by early 2021. COVID-19 is a new strain of coronavirus that has not been previously identified in humans. The COVID-19 is the cause of an outbreak of respiratory illness first detected in Wuhan, Hubei province, China. Since December 2019, cases have been identified in a growing number of countries. The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 118,567 lives till 25th October 2020 in the country1. Source : Ministry of Health and Family Welfare dated 27 th Oct 2020 The whole world is waiting eagerly for an effective vaccine to fight the coronavirus pandemic.
    [Show full text]
  • Vaccine Matri: a New Way of Diplomacy
    AN EXPLORATORY STUDY OF ROLE OF INDIA IN VACCINE DIPLOMACY FOR COVID-19 PANDEMIC ERA Turkish Online Journal of Qualitative Inquiry (TOJQI) Volume 12, Issue 3, June 2021:652- 665 Research Article An Exploratory Study Of Role Of India In Vaccine Diplomacy For Covid-19 Pandemic Era Dr. Saroj Choudhary1, Dr Sanjiv Singh Bhadauria2, Mr Abhinav Upadhyay3, Dr Sandeep Kulshrestha4 Abstract Coronavirus is spread in end of December, 2019 in Wuhan and in March, 2020 World Health Organization declared it as a pandemic. Coronavirus affect world in many ways like socially, economically and in many other. In early January, 2021 India make their vaccine and not only vaccinated their own people but also help other countries and provide vaccine to their neighbouring countries on grant and commercial basis and this will help India to make their reputation in world platform. In this paper, Vaccine Maîtri an initiative by India to provide vaccine to their neighbouring countries and also other needy countries and how this will enhance the image of India in world stage. Keywords: Coronavirus; COVID-19; vaccine maîtri; vaccine; India;government; WHO. VACCINE MATRI: A NEW WAY OF DIPLOMACY COVID-19 is a major global public health challenge, and in many countries it has created a serious social, economic, and political crisis. The numbers involved are staggering, whether they refer to infection and death, the rate of public health measures such as travel restrictions, or the economic consequences of unemployment and public sector spending. All economies are placed in drug-induced comas, the complex public health systems have become increasingly prevalent in levels of public adherence or surprising disobedience, and health care systems and provinces are being tested by many who have never seen it.
    [Show full text]
  • White Paper on the Management of COVID-19 by the Government of India
    White Paper on the Management of COVID-19 by the Government of India JUNE 2021 TABLE OF CONTENTS 1. Executive Summary…………………………………………... (i) 2. The Need for a White Paper on the Management of the COVID-19 Pandemic………………………………….. 1 3. Early Inaction Against COVID-19………………………….. 5 4. Policy Response to the First Wave………………………… 10 5. Hubris and Political Avarice………………………………… 18 6. Ignoring the Signs and the Science………………………... 27 7. Unforgivable Negligence…………………………..…………. 41 8. Vaccine Mismanagement..……………………………...…… 51 9. Wider Impact of Policy Failures…………………………….. 82 10. The Way Ahead……………………………………………….. 89 11. Annexure 1. Indian National Congress: Compendium of Statements, Letters and Resolutions on COVID-19 (March 2020 - June 2021)…………………………………… A1 Executive Summary The mismanagement of the COVID-19 pandemic has been independent India’s gravest governance failure. The Union government under Prime Minister Narendra Modi did not take adequate measures to prevent and contain the pandemic. Therefore, there is a Need for a White Paper (Chapter-1) that examines the government’s acts of omission and commission, its impact on India and suggests constructive measures to improve policy responses to the current and future waves of the pandemic. The Modi government’s handling of the COVID-19 crisis began with its Early Inaction in January 2020 (detailed in Chapter-2). The government ignored early warnings from experts and political leaders from the Opposition. It failed to learn from the lessons and response models of other countries which had been hit by the pandemic. It did not scale up nationwide the lessons from Kerala’s experience in successfully suppressing a virus outbreak (the Nipah virus).
    [Show full text]
  • Announcement on Procurement Process
    Announcement on Procurement Process During the past few weeks, there have been reports in the media at large misrepresenting the procurement process of COVAXIN®, in Brazil and other countries. We wish to provide the following clarification - ∙ The procurement process for COVID-19 vaccines and several vaccines for routine immunization follow a common process which is widely accepted, and established in Industry ∙ Based on a country’s requirement, the company receives a letter of intent (or MOU) for procurement ∙ The company then proceeds to apply for emergency use authorization (EUA) in the respective country ∙ Once EUA is received, the Ministry of Health (MOH) would proceed to place a firm order by releasing a purchase order, with the required initial quantities. In several countries, MOHs have placed orders for procurement prior to the approval of vaccines such as USA, EU, India, etc. However, procurement happens only post EUA. ● In order to secure a firm Purchase Order from the country, the company proceeds to raise a Pro Forma Invoice to the MOH, towards the supply of vaccine ● Based on the invoice, the MOH pays the amount in advance ● Once the payment is received, the company proceeds to supply the agreed quantities and within the agreed timelines ● In the specific case of procurement of COVAXIN® by MOH Brazil, since the first meetings with MOH Brazil during Nov 2020, until 29th of June 2021, a step-by-step approach has been followed towards contracts, and regulatory approvals, during this ~ 8 long month-long process. On 4th June 2021, ANVISA authorized the exceptional import of the Covaxin vaccine by the Ministry of Health for distribution and Use Under Controlled Conditions”.
    [Show full text]
  • India: the World's Pharmacy Expands Its Reach in Global Health
    New York | New Delhi | Rio de Janeiro Nairobi | Johannesburg | London India: The World’s Pharmacy Expands Its Reach in Global Health March 2021 This white paper was last updated on 1 March 2021 Global Health Strategies 18/1, 2nd Floor Shaheed Bhawan, Aruna Asaf Ali Marg, New Delhi, 110 067 www.globalhealthstrategies.com Twitter: @GHS Contents Executive Summary 02 India’s response to COVID-19 03 ∙ Pharmaceuticals and Biosimilars 04 ∙ Vaccines 05 ∙ Diagnostics 06 Evolution of India’s pharmaceutical industry 07 ∙ Milestones 08 Case Studies ∙ Hepatitis B Vaccine 10 ∙ Anti-retroviral Drugs 11 ∙ MenAfriVac 12 ∙ Complex Generics 13 ∙ Insulin 14 ∙ Monoclonal Antibodies 15 ∙ Vaccine for Rotavirus 16 ∙ Typhoid Conjugate Vaccine 17 Conclusion: Looking Forward 18 Executive Summary India’s pharmaceutical industry is already playing a pivotal role in the scale-up of pharmaceuticals and diagnostics to combat the global COVID-19 pandemic. It is poised to play an even more dominant role as biological products – preventive vaccines and cutting-edge biotechnology such as monoclonal antibodies– come to the fore. Even before the pandemic, Indian manufacturers produced vast quantities of generic antiviral drugs that turned HIV from a death sentence to a chronic manageable condition in developing countries. India’s global dominance in generic drugs and vaccine manufacturing has earned it the label “Pharmacy of the World”. COVID-19 only strengthens the case for this moniker. So far, India has supplied medicines to 133 countries to fight the pandemic. Six Indian manufacturers have been granted royalty-free licenses by Gilead to manufacture the first antiviral drug approved by the U.S.
    [Show full text]
  • CME INDIA COVID-19 Vaccination Protocol 2021 July Updat
    COVID-19 VACCINATION PROTOCOL JULY 21 CME INDIA CME 1 CME INDIA CME INDIA COVID-19 Vaccination Protocol First published: 29th April 2021. Last Updated: 6th July 2021. With the rapid rise in Covid-19 cases in INDIA, CME INDIA has now compiled its own vaccination protocol with inputs from key medical experts. The goal of this document is to help the medical community in managing the current Covid-19 situation and provide insight into the COVID-19 Vaccination Program in India. This document will be updated from time to time, so please check www.cmeindia.in and CME INDIA Downloads section regularly. Alternatively, you can choose to navigate to the various key sections of CME INDIA: Explore CME INDIA Repository Examine CME INDIA Case Study Read History Today in Medicine Register for Future CMEs View CME INDIA Downloads 2 CME INDIA 3 CME INDIA Basic Framework By: Dr. Akash Singh, MD (Med) MSc (Diabetes) Consultant Physician and Diabetologist Spandan Multi Speciality Hospital, Vadodara. Dr. S. K. Gupta, MD (Med), FICP, CFM(France) Clinical Asst. Professor GS Medical College, CCSU, Uttar Pradesh India. Visiting Consultant, Max Super Specialty Hospital, New Delhi. Dr. Kiran Shah, Consultant Physician MBBS, MD, Spandan Multi Speciality Hospital Vadodara. Edited By: Dr. N.K. Singh, MD, FICP, Diabetologist Physician, Dhanbad, Editor - cmeindia.in. Advisor and Reviewer: Dr. Awadhesh Kumar Singh, Consultant Endocrinologist, G. D. Hospital & Diabetes Institute, Kolkata, West Bengal. Invitee Reviewer: Dr. Banshi Saboo, National President, RSSDI, Ahmedabad. Dr. Mangesh Tiwaskar, Consultant Physician & Diabetologist, Mumbai, Hon. General Secretary, API. Reviewer: Dr. R. Rajasekar, MD, FICP, FACP (USA), FRCP (Glasgow), FRCP (Ireland), Consultant Physician & Diabetologist Heart & Diabetes Therapy Centre, Kumbakonam, Tamil Nadu.
    [Show full text]
  • Strategy for COVID-19 Vaccination in India: the Country with the Second Highest Population and Number of Cases ✉ Velayudhan Mohan Kumar 1, Seithikurippu R
    www.nature.com/npjvaccines PERSPECTIVE OPEN Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases ✉ Velayudhan Mohan Kumar 1, Seithikurippu R. Pandi-Perumal 2 , Ilya Trakht3 and Sadras Panchatcharam Thyagarajan 4 Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home- grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. npj Vaccines (2021) 6:60 ; https://doi.org/10.1038/s41541-021-00327-2 1234567890():,; INTRODUCTION eight vaccine candidates, currently undergoing clinical trials in A year has passed since the first case of novel coronavirus India, is shown in Table 1 and their technical details are given in 13 infections was detected in China’s Wuhan province.
    [Show full text]
  • Highlights India Situation
    HIGHLIGHTS Prime Minister Office reviewed planning and preparations for vaccination against Covid-19 details here. With the announcement of WHO Situation Update 166 COVAXIN by Bharat Biotech and ZyCov-D Vaccine by Zydus Cadila, India Drug Controller General - CDSCO (The Central Drugs Standard Control Organization) approved human trials for the vaccines, details here. 648,315 Confirmed Cases 18,655 Total Deaths Union Ministry of Home Affairs (MHA) issued guidelines for Unlock 2 to open up of activities in areas outside the Containment Zones into effect South East Asia Region from July 1, 2020, details here. 888,732 Confirmed Cases 23,774 Total Deaths Removal of obstructions paves the way for ramped up COVID-19 testing as Private Practitioner can also prescribe a COVID-19 test. World Government of India reiterated that ‘test-track-treat’ is the key 10,922,324 Confirmed Cases strategy for early detection and containment of the pandemic, details 523,011 Deaths here. INDIA SITUATION As on 05 July 2020, 08:00 IST there were 244,814 Active Cases, 409,082 Cured/Discharged, 1 Migrated and 19,268 Deaths in India. Collective and focused efforts of containment and management of COVID-19 by center and the States/UTs have led to rise in recovered cases among COVID-19 patients (figure below) details here. RECOVERY RATE AMONG CONFIRMED CASES ACROSS STATES WITH THE HIGHEST COVID-19 BURDEN 1st Week of June 1st week of July 80% 77% 74% 72% 70% 69% 69% 68% 67% 61% 60% 57% 54% 54% 53% 50% 47% 43% 41% 36% INDIA DELHI NADU TAMIL WEST MAHA UTTAR BENGAL MADHYA GUJARAT RASHTRA PRADESH PRADESH RAJASTHAN KARNATAKA Source: MoHFW Government of India COVID-19 as on: 05 July 2020, 08:00 IST (GMT+5:30) Ministry of Health and Family Welfare Government of India WHO GLOBAL UPDATE • WHO accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms, details here.
    [Show full text]
  • FAIRFAX News Release TSX Stock Symbol: FFH and FFH.U
    FAIRFAX News Release TSX Stock Symbol: FFH and FFH.U TORONTO, April 20, 2020 FAIRFAX TO DONATE US$1 MILLION TO ‘PM CARES FUND’ FOR COVID-19 RELIEF IN INDIA Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U), recognizing the unprecedented widespread economic suffering from the COVID-19 pandemic, is donating US$1 million to the Prime Minister’s Citizen Assistance and Relief in Emergency Situations Fund (the “PM CARES Fund”) to aid the Indian Government in providing assistance to its citizens in connection with the COVID-19 pandemic. The donation will be made to the PM CARES Fund on behalf of the Fairfax group of companies, including Fairfax India Holdings Corporation, through Fairfax’s Indian affiliate Fairbridge Capital Private Limited. The PM CARES Fund, chaired by Prime Minister Narendra Modi, was created to provide relief to those affected by the COVID-19 pandemic in India, including the provision of financial assistance to Indian citizens and to support healthcare and other necessary infrastructure. Prem Watsa, Chairman and Chief Executive Officer of Fairfax, commented, “We have been impressed by the Indian government’s rapid and proactive response to the COVID-19 pandemic, including the implementation of one of the strictest lockdowns in the world. Fairfax wishes to assist the Indian Government in its efforts to support many of the most vulnerable members of Indian society, who will be severely impacted by the pandemic.” Fairfax is a holding company which, through its subsidiaries, is engaged in property and casualty insurance and reinsurance and the associated investment management. -30- For further information contact: John Varnell, Vice President, Corporate Development at (416) 367-4941 FAIRFAX FINANCIAL HOLDINGS LIMITED 95 Wellington Street West, Suite 800, Toronto, Ontario, M5J 2N7 Telephone: 416-367-4941 Facsimile: 416-367-4946 .
    [Show full text]
  • Indian Apis & Formulations for Global Healthcare
    PRICE LICENSED TO POST WITHOUT PREPAYMENT PER COPY LICENCE NO. MR/Tech/WPP-337/West/2021-23 ` RNI REGN. NO. 18921/1970 25/- REGN NO. MCW/95/2021-23 vol. NO. 52 ISSUE NO. 18 (Pages: 40) 08 TO 14 MAY 2021 ISSN 0970-6054 WEEKLY PUBLICATION Indian APIs & Formulations for Global Healthcare Unprecedented increase in the prices of Active Pharmaceutical Ingredients (API) : IDMA Representation to NPPA (Page No. 9) Press Release: IDMA Recommends Grant of “Voluntary Licenses (Vl)” IDMAfor Vaccines Submission by the on Patent Draft GuidelinesHolders to forIndian dealing Companies cases with ofSufficient discontinuation Expertise of in Scheduled this Field Formulations (Page No. 11) (Page No. 4) ‘WhyIDMA Phytopharmaceutical Representation to Minister Drug Discovery?’ of State for by Chemicals Dr S S Handa & Fertilizers (Pageon PLI No. 6)Scheme (Page No. 13) Advisory:Department COVID-19 of Pharmaceuticals – Amendments/Relaxations/Compliances Re-invites application for Production (PageLinked No. 8)Incentive (PLI) Scheme with the last date of Submission as th Export28 July restrictions 2021 (Page on No.Hydroxychloroquine 15) lifted (Page No. 19) Fight Covid with compulsory licensing (Page No. 20) IDMA Bulletin DoP LII (18)comes 08 to 14 out May with2021 draft Guidelines for Rs.6,940 crore PLI scheme1 toGST promote waiver domesticon Covid productionjabs, drugs ofwill Bulk backfire: Drugs FM (Page Nirmala No. 32) Sitharaman (Page No. 27) IDMA Bulletin LII (18) 08 to 14 May 2021 2 Founder Editor: Vol. No. 52 Issue No. 18 08 to 14 May 2021 Dr A Patani IDMA ACTIVITIES: Editor: Dr Gopakumar G Nair The Journey so far and the Roadmap Ahead .................................................................
    [Show full text]